Administration of Low-dose IL-2 in Established T1D

Conditions:   Diabetes Mellitus, Type 1;   Diabetes;   Diabetes, Autoimmune Interventions:   Drug: Proleukin® (Aldesleukin; IL-2);   Drug: Placebo - Concentrate Sponsors:   Jay S. Skyler;   National Institute of Allergy and Infectious Diseases (NIAID);   Diabetes Research Institute Foundation;   University of Florida;   University of California, San Francisco Not yet recruiting - verified August 2017
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials